869368-48-9 Usage
Description
(2S,3S,5S)-2,5-bis-[N-[N-[[N-methyl-N-[(2-isopropyl-4-thiazolyl)methyl]amino]carbonyl]valinyl]amino]-1,6-diphenyl-3-hydroxyhexane is a complex organic compound with a unique molecular structure. It is characterized by its chiral centers at the 2nd, 3rd, and 5th positions, which are all in the S configuration. (2S,3S,5S)-2,5-bis-[N-[N-[[N-methyl-N-[(2-isopropyl-4-thiazolyl)methyl]amino]carbonyl]valinyl]amino]-1,6-diphenyl-3-hydroxyhexane features a 1,6-diphenyl-3-hydroxyhexane core, with two N-methyl-N-[(2-isopropyl-4-thiazolyl)methyl]amino]carbonyl]valinyl]amino groups attached at the 2nd and 5th positions. This intricate molecular arrangement may confer specific properties and potential applications in various fields.
Uses
Used in Pharmaceutical Industry:
(2S,3S,5S)-2,5-bis-[N-[N-[[N-methyl-N-[(2-isopropyl-4-thiazolyl)methyl]amino]carbonyl]valinyl]amino]-1,6-diphenyl-3-hydroxyhexane is used as an impurity in the production of Ritonavir (R535000), a selective HIV protease inhibitor. Its presence as an impurity in Ritonavir is significant, as it can affect the drug's efficacy, safety, and quality. Rigorous quality control measures are necessary to ensure that the levels of this impurity are within acceptable limits, thereby maintaining the overall effectiveness and safety of the medication.
Check Digit Verification of cas no
The CAS Registry Mumber 869368-48-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,9,3,6 and 8 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 869368-48:
(8*8)+(7*6)+(6*9)+(5*3)+(4*6)+(3*8)+(2*4)+(1*8)=239
239 % 10 = 9
So 869368-48-9 is a valid CAS Registry Number.
869368-48-9Relevant articles and documents
RITONAVIR ANALOGOUS COMPOUND USEFUL AS RETROVIRAL PROTEASE INHIBITOR, PREPARATION OF THE RITONAVIR ANALOGOUS COMPOUND AND PHARMACEUTICAL COMPOSITION FOR THE RITONAVIR ANALOGOUS COMPOUND.
-
Page/Page column 20-21, (2010/02/14)
The present invention describes a new one ritonavir analogous compound that presents significantly superior activity in inhibition of HIV protease. There are also described the usage of the ritonavir analogous compound of the present invention or salt, ester or prodrug thereof as well as the usage of the compound and its pharmaceutical compositions in medicine, particularly, in the treatment of HIV infection, by itself or in combination with others anti-HIV drugs.
